Assessment of Host-targeted Nanobody Therapeutics
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DEFENSE HEALTH AGENCY
Contract Value
Not provided
Codes & Classification
Solicitation Number
HT942626QE003
NAICS
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Classification Code
AJ11
Additional Details
Documents1
The Defense Health Agency (DHA), in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), has issued a Request for Information (RFI) seeking industry input and capability statements for the "Assessment of Host-targeted Nanobody Therapeutics." This RFI, identified under procurement number HT942626QE003, is intended to inform the planning and potential future solicitation of an Indefinite Delivery/Indefinite Quantity (IDIQ) contract. The primary focus is on evaluating host-targeted nanobody therapies using advanced in vitro blood-brain barrier (BBB) models, with the ultimate goal of advancing therapeutic strategies against neurotropic viral infections that pose significant threats to military and public health.
**Purpose and Scope**
The overarching objective of this procurement is to identify qualified contractors capable of providing comprehensive services for the assessment and development of host-targeted nanobody therapeutics. The contractor will be responsible for supplying all necessary personnel, equipment, materials, and expertise to evaluate nanobody therapies using established and novel in vitro BBB models, particularly those based on porcine and non-human primate (NHP) systems. The scope also includes the development and refinement of these models to better characterize the mechanisms by which nanobodies traverse the BBB, a critical barrier in the treatment of central nervous system (CNS) infections.
**Key Requirements and Expected Deliverables**
Contractors responding to this RFI should demonstrate expertise in the following areas:
- Refinement and application of in vitro BBB models for the assessment of nanobody transmigration, especially in the context of viral infection.
- Characterization of porcine BBB arenavirus infection models and establishment of marmoset (NHP) BBB models.
- Determination of baseline and targeted transmigration efficiencies for nanobody therapies, with comprehensive reporting on methods, data, and analysis.
- Delivery of validated BBB models and detailed characterization reports, with validation criteria subject to government approval.
- Provision of subject-matter expertise and advisory support to USAMRIID, documented through meeting minutes, reports, and other formal communications.
Each task order under the anticipated IDIQ contract will specify unique deliverables, requiring flexibility in design, scheduling, and execution. Administrative deliverables will include study protocols, budgets, integrated master schedules, market sustainment plans, monthly and quarterly progress reports, spend plans, and a final study report. Performance will be monitored through a Quality Assurance Surveillance Plan (QASP), which may be negotiated prior to contract award.
**Contracting Entity and Location**
The contracting activity is managed by the Defense Health Agency (DHA), a federal office under the Department of Defense. The primary place of performance is at the contractor’s facility, with the government’s technical oversight based in Frederick, Maryland. The contract will have a five-year ordering period, with a potential six-month extension under FAR 52.217-8 if required.
**Classification and Contact Information**
- **NAICS Code:** 541715 – Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- **Product Service Code:** AJ11
- **Set-Aside Status:** None (open to all qualified offerors)
- **Primary Contact:** Grant A. Gratton ([email protected], 301-619-2593)
- **Secondary Contact:** Emily K. O’Hara ([email protected], 301-619-9599)
- **Notice URL:** [SAM.gov Opportunity](https://sam.gov/opp/d8cb9ce093654279995607bca4a4b9eb/view)
**Special Considerations**
This RFI is for informational and planning purposes only and does not constitute a solicitation or a request for proposals. No contract will be awarded based solely on responses to this notice. All responses must be submitted electronically in Microsoft Office format, not exceeding three pages, and should be marked as proprietary if applicable. The government will treat all submissions as business confidential information.
Contractors are encouraged to utilize the Defense Technical Information Center (DTIC) and other government-controlled sources to ensure their proposed approaches build upon existing knowledge and avoid unnecessary duplication of effort.
**Conclusion**
This opportunity is well-suited for organizations with advanced capabilities in BBB modeling, virology, and therapeutic assessment, particularly those experienced in translational research for CNS-targeted therapies. The flexible, task order-driven structure of the anticipated IDIQ contract allows for a range of specialized research and development activities, supporting the government’s mission to protect military personnel and the public from emerging biological threats. Interested parties should carefully review the requirements and submit a comprehensive capabilities statement by the specified deadline to be considered for future engagement.